Last reviewed · How we verify
NCT05011032
Effects of Homocysteine in Myocardial Infarction Patients in a Tertiary Care Hospital of Pakistan
NA trial testing Homocysteine in Homocystine; Metabolic Disorder. Withdrawn.
9 September 2021
Quick facts
| Lead sponsor | Aqua Medical Services (Pvt) Ltd |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | diagnostic |
| Start date | 12 August 2021 |
| Primary completion | 9 September 2021 |
| Estimated completion | 12 September 2021 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Homocysteine
Conditions studied
- Homocystine; Metabolic Disorder — all drugs for Homocystine; Metabolic Disorder →
Sponsor
Aqua Medical Services (Pvt) Ltd
Who can join
Adults 18 to 45, any sex, with Homocystine; Metabolic Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Raised plasma Homocysteine (Hcy) was 1st proposed as a cause of vascular pathology in patients with inherited disorders of Homocysteine metabolism.leading to the hypothesis that individuals with slight to moderate elevated levels of Homocysteine may have an increased hazard for vascular disease. As an amino acid with a reactive sulfhydryl group, homocysteine has been proposed to intermediate vascular inflammation and damage by stimulating oxidative stress secondary to reactive oxygen species accumulation. which in turn leads to an rise in cardiac and vascular disease risk by stimulating endothelial dysfunction, smooth muscle cell proliferation, and vascular calcification. Consistent with this hypothesis, hyperhomocysteinemia a has been associated with an increased risk for coronary heart disease (CHD), heart failure, atrial fibrillation, stroke, and mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05011032
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Aqua Medical Services (Pvt) Ltd trials
Trials by the same sponsor.
- NCT04930523 — Effect of Decompression With and Without ELDOA in Lumber Disc Protrusion Patients · NA · completed
- NCT04860609 — Compare the Effects of Decompression on Lumber Disc Protrusion Patient · NA · completed
- NCT04733261 — Diaphragmatic Mobility In Ventilated Assisted Patients · NA · completed
- NCT04733248 — kINESIOTAPING ON PATIENT'S FUNCTIONAL STATUS IN NON-SPECIFIC NECK PAIN · NA · completed
- NCT04760210 — Decompression With ELDOA on Lumbar Disc Protrusion Patient · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05011032 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aqua Medical Services (Pvt) Ltd
- Last refreshed: 10 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05011032.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing